| Literature DB >> 30166901 |
Salvador Enrique Meneses-Sagrero1, Moisés Navarro-Navarro2, Eduardo Ruiz-Bustos2, Carmen Lizette Del-Toro-Sánchez3, Manuel Jiménez-Estrada4, Ramón Enrique Robles-Zepeda2.
Abstract
Cancer is the major cause of death in the world, representing a significant public health problem. Plants have been shown as a great source of secondary metabolites with anticancer activity. The aim of this work was evaluated the antiproliferative activity of the methanolic extracts, chemical fractions and the compound spinasterol isolated of medicinal plant Stegnosperma halimifolium. The methanolic extracts of stem, leaf and stem/leaf was obtained by maceration. The methanolic extract of stem was purified by successive extractions with solvents as n-hexane, ethyl acetate and ethanol. The n-hexane fraction was separated by column chromatographic and monitored by thin layer chromatographic. The compound spinasterol was characterized by 1H NMR, 13C NMR and Mass Spectrometry. Methanolic extracts, chemical, chromatographic fractions and spinasterol was evaluated against RAW 264.7, M12.C3.F6, PC-3, LS-180, A549 and HeLa cancer cell lines by the standardized method MTT for determinate the antiproliferative activity. Methanolic extract of stem shown the better antiproliferative activity against the murine macrophage cancer cell line RAW 264.7. n-Hexane chemical fraction shown antiproliferative activity against human alveolar cancer cell line A549 and RAW 264.7. Was isolated and characterized a compound by NMR 1H and 13C, revealing the presence of sterol spinasterol. Spinasterol shown to have antiproliferative activity against cervical cancer cell line HeLa and RAW 264.7, indicating that spinasterol can be a responsible compound of antiproliferative activity found in the methanolic extract of Stegnosperma halimifolium.Entities:
Keywords: Antiproliferative activity; Spinasterol; Stegnosperma halimifolium; Stegnospermaceae
Year: 2017 PMID: 30166901 PMCID: PMC6111116 DOI: 10.1016/j.jsps.2017.07.001
Source DB: PubMed Journal: Saudi Pharm J ISSN: 1319-0164 Impact factor: 4.330
Evaluation of antiproliferative activity of methanolic extracts from S. halimifolium against human cancer cell line A549, HeLa, LS-180, PC-3; murine cancer cell line RAW 264.7, M12.C3.F6 and murine non-cancer cell line L-929.
| Methanolic extract | IC50 | ||||||
|---|---|---|---|---|---|---|---|
| L-929 | RAW 264.7 | M12.C3.F6 | HeLa | A549 | LS-180 | PC-3 | |
| Stem + Leaves | >400 | 243.12 ± 1.5 | 213.67 ± 1.3 | >400 | >400 | >400 | >400 |
| Stem | >400 | 118.09 ± 1.75 | >400 | >400 | >400 | >400 | >400 |
| Leaves | >400 | >400 | >400 | >400 | >400 | >400 | >400 |
| Doxorubicin | 2.89 ± 0.11 | 0.38 ± 0.01 | 1.89 ± 0.06 | >4 | 2.5 ± 1.4 | 3.8 ± 0.1 | 3.1 ± 0.3 |
Half maximal inhibitory. The results are expressed as average ± Standard Deviation.
Positive control.
Significative differences (p < 0.05) comparing to L-929 cell line. Maximum concentration evaluated 400 μg/mL.
Evaluation of antiproliferative activity of fractions generated from the methanolic extract of the stem of S. halimifolium against human cancer cell line A549, HeLa, PC-3, LS-180, murine cancer cell line RAW 264.7 and M12.C3.F6 and non-cancer cell line L-929.
| Fraction | IC50 | ||||||
|---|---|---|---|---|---|---|---|
| L-929 | RAW 264.7 | M12.C3.F6 | HeLa | A549 | LS-180 | PC-3 | |
| 133.4 ± 1.4 | 65.9 ± 1.1 | 146.1 ± 1.4 | 343.2 ± 2.4 | 68.6 ± 1.3 | >400 | >400 | |
| Ethyl Acetate | 215.8 ± 2.1 | 50.8 ± 1.1 | 78.4 ± 1.3 | 130.9 ± 1.1 | 349.7 ± 1.2 | >400 | >400 |
| Ethanol | NP | NP | NP | NP | NP | NP | NP |
| Doxorubicin | 2.89 ± 0.11 | 0.38 ± 0.01 | 1.89 ± 0.06 | >4 | 2.5 ± 1.4 | 3.8 ± 0.1 | 3.1 ± 0.3 |
Half maximal inhibitory. The results are expressed as average ± Standard Deviation.
Positive control. NP: Not Activity Present.
Significative differences (p < 0.05) comparing to L-929 cell line. Maximum concentration evaluated 400 μg/mL.
Qualitative phytochemical analysis of the n-hexane, ethyl acetate and ethanol fraction obtained of the methanolic extract of stem of Stegnosperma halimifolium.
| Test | Ethyl acetate fraction | Ethanol fraction | |
|---|---|---|---|
| Rosenthaler | − | − | − |
| Foam | − | − | + |
| KOH | − | − | − |
| Wagner | − | − | − |
| Meyer | − | − | − |
| Gelatin | − | − | − |
| NaOH 10% | − | + | + |
| CHCl3 | − | − | − |
| FeCl2 | − | − | + |
| Keller – Kiliani | − | − | − |
| Liebermann – Buchnard | + | − | − |
(−) Negative test. (+) Positive test. Cholesterol for terpenes test, quercetin for flavonoids test, gallic acid for tannins and phenolic compound test and berberine for alkaloids test were used as positive control.
Evaluation of antiproliferative activity of column chromatographic fractions of the n-hexane fraction of S. halimifolium against A549 human cancer cell line.
| Chromatographic fraction | IC50 |
|---|---|
| 1 | >100 |
| 2 | 71.9 ± 1.08 |
| 3 | >100 |
| 4 | 84.71 ± 1.32 |
| 5 | 81.13 ± 1.21 |
| 6 | 71.86 ± 1.29 |
| 7 | 60.45 ± 1.2 |
| 8 | >100 |
| 9 | 63.4 ± 1.14 |
| 10 | 55.22 ± 1.09 |
| 11 | 57.39 ± 1.13 |
| 12 | 73.91 ± 1.17 |
| 13 | 84.65 ± 1.12 |
| 14 | >100 |
| 15 | 96.48 ± 1.6 |
| 16 | 95.69 ± 1.19 |
Half maximal inhibitory. The results are expressed as average ± Standard Deviation. Maximum concentration evaluated 100 μg/mL.
Chemical displacements of 13C and 1H NMR of chromatographic fraction 8 and spinasterol.
| Position | RMN 13C (δ) ppm | RMN 1H (δ) ppm | Spinasterol 13C (1H) |
|---|---|---|---|
| 1 | 37.155 | 1.01, 1.74 | 37.1 (1.09, 1.82) |
| 2 | 31.479 | 1.36, 1.72 | 31.5 (1.39, 1.77) |
| 3 | 71.079 | 3.52 (1H, m) | 71.1 (3.6, 1H, m) |
| 4 | 37.997 | 1.18, 1.63 | 38.0 (1.27, 1.70) |
| 5 | 40.275 | 1.33 | 40.3 (1.4) |
| 6 | 29.69 | 1.15, 1.68 | 1.22, 1.74 |
| 7 | 117.46 | 5.09 (1H, m) | 117.5 (5.18, 1H, m) |
| 8 | 139.56 | – | 139.6 |
| 9 | 49.466 | 0.66 | 49.5 (1.66) |
| 10 | 34.23 | – | 34.24 |
| 11 | 21.555 | 1.5 | 21.6 (1.48) |
| 12 | 39.476 | 1.18, 1.92 | 39.6 (1.23, 2.0) |
| 13 | 43.29 | – | 43.3 |
| 14 | 55.135 | 1.74 | 51.15 (1.81) |
| 15 | 23.086 | 1.31, 1.44 | 23.0 (1.40, 1.52) |
| 16 | 28.498 | 1.2, 1.66 | 28.5 (1.25) |
| 17 | 55.918 | 1.18 | 55.95 (1.25) |
| 18 | 12.049 | 0.5 | 12.05 (0.55) |
| 19 | 13.037 | 0.72 | 13.0 (0.8) |
| 20 | 40.817 | 1.97 | 40.8 (2.05) |
| 21 | 21.372 | 1.5 | 21.4 (1.02) |
| 22 | 138.158 | 5.1 (1H, dd) | 138.15 (5.17, 1H, dd) |
| 23 | 129.457 | 4.983 (1H, dd) | 129.48 (5.09. 1H, dd) |
| 24 | 51.253 | 1.45 | 51.26 (1.55) |
| 25 | 31.874 | 1.48 | 31.9 (1.55) |
| 26 | 21.079 | 0.75 | 21.2 (0.85) |
| 27 | 18.99 | 0.72, 0.85 | 19.0 (0.84) |
| 28 | 25.393 | 1.09, 1.33 | 25.4 (1.18, 1.42) |
| 29 | 12.24 | 0.75 | 12.2 (0.81) |
Chemical displacements expressed in (δ) ppm. Varian INOVA. 500 MHz (1H), 125 MHz (13C). CDCl3. (dd): Double of double. (m): Multiplete.
Fig. 1Chemical structure of spinasterol.
Fig. 2COSY analysis for the identification of spinasterol.
Fig. 3HMBC analysis for the identification of spinasterol.
Evaluation of antiproliferative activity of spinasterol against human cancer cell lines LS-180, A549, PC-3, HeLa and murine cancer cell line RAW 264.7.
| Cell line | IC50 |
|---|---|
| Spinasterol | |
| LS-180 | >100 |
| A549 | >100 |
| PC-3 | >100 |
| HeLa | 77.1 ± 2.1 |
| RAW 264.7 | 69.2 ± 6 |
Half maximal inhibitory. The results are expressed as average ± Standard Deviation. Maximum concentration evaluated of 100 μg/mL.